azomycin has been researched along with Deafness, Transitory in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (60.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bali, S; Bhutta, MF; Brown, SD; Cheeseman, MT; Hilton, H; Hough, TA; Parker, A; Pathak, P; Potter, PK; Purnell, T; Romero, MR; Tyrer, HE; Vizor, L; Vowell, K; Wells, S; Williams, D | 1 |
| Donadieu, E; Lavieille, JP; Magnan, J; Riva, C | 1 |
| Kogelnik, HD | 1 |
| Johnson, RJ; Levin, VA; Phillips, TL; VanRaalte, G; Wasserman, TH | 1 |
| Black, BE; Bush, RS; Cummings, BJ; Rauth, AM; Sorenti, VL; Thomas, GM | 1 |
2 trial(s) available for azomycin and Deafness, Transitory
| Article | Year |
|---|---|
Clinical experience with misonidazole: high dose fractions versus daily low doses.
Topics: Adult; Aged; Blood Pressure; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Eruptions; Epilepsy; Female; Hearing Loss; Humans; Male; Middle Aged; Misonidazole; Neurocognitive Disorders; Nitroimidazoles; Peripheral Nervous System Diseases | 1980 |
A phase I study of misonidazole and pelvic irradiation in patients with carcinoma of cervix.
Topics: Double-Blind Method; Drug Evaluation; Female; Hearing Loss; Humans; Kinetics; Misonidazole; Nitroimidazoles; Peripheral Nervous System Diseases; Random Allocation; Thrombocytopenia; Uterine Cervical Neoplasms | 1982 |
3 other study(ies) available for azomycin and Deafness, Transitory
| Article | Year |
|---|---|
HIF-VEGF pathways are critical for chronic otitis media in Junbo and Jeff mouse mutants.
Topics: Animals; Blister; Body Fluids; Cell Hypoxia; Disease Models, Animal; Ear, Middle; Gene Expression Regulation; Hearing Loss; HSP90 Heat-Shock Proteins; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Indoles; Mice; Mice, Inbred C3H; Mice, Inbred C57BL; Mice, Mutant Strains; Nitroimidazoles; Otitis Media with Effusion; Phthalazines; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sunitinib; Vascular Endothelial Growth Factor A | 2011 |
Age-related hearing loss in CD/1 mice is associated to ROS formation and HIF target proteins up-regulation in the cochlea.
Topics: Action Potentials; Aging; Animals; Apoptosis; Caspase 3; Cochlea; Cochlear Nerve; Coloring Agents; Hearing Loss; Hypoxia; Hypoxia-Inducible Factor 1, alpha Subunit; Immunohistochemistry; Injections, Intravenous; Insulin-Like Growth Factor I; Mice; Nitroimidazoles; Reactive Oxygen Species; Schwann Cells; Spiral Ganglion; Tumor Necrosis Factor-alpha; Tumor Suppressor Protein p53; Up-Regulation | 2007 |
Final report on the United States Phase I Clinical Trial of the hypoxic cell radiosensitizer, misonidazole (Ro-07-0582; NSC #261037).
Topics: Adolescent; Adult; Aged; Central Nervous System Diseases; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Evaluation; Female; Hearing Loss; Humans; Male; Middle Aged; Misonidazole; Nausea; Nitroimidazoles; Peripheral Nervous System Diseases; Vomiting | 1981 |